Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C21H16F2N4O3S and a molecular weight of approximately 442.44 g/mol. It belongs to the class of aryl phenylketones and features both difluorophenylene and pyrrolopyridine moieties. The compound is listed as an experimental drug in DrugBank (DB07000), but there is no publicly available information on its clinical development status or therapeutic indication. Its mechanism of action has not been explicitly described in public databases; however, based on its structure—particularly the presence of a pyrrolopyridine core—it may have been investigated as a kinase inhibitor or for other protein-targeting activities typical for this scaffold class.[1][2][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide.